 |
PDBsum entry 4zmj
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Viral protein
|
PDB id
|
|
|
|
4zmj
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nat Struct Biol
22:522-531
(2015)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env.
|
|
Y.D.Kwon,
M.Pancera,
P.Acharya,
I.S.Georgiev,
E.T.Crooks,
J.Gorman,
M.G.Joyce,
M.Guttman,
X.Ma,
S.Narpala,
C.Soto,
D.S.Terry,
Y.Yang,
T.Zhou,
G.Ahlsen,
R.T.Bailer,
M.Chambers,
G.Y.Chuang,
N.A.Doria-Rose,
A.Druz,
M.A.Hallen,
A.Harned,
T.Kirys,
M.K.Louder,
S.O'Dell,
G.Ofek,
K.Osawa,
M.Prabhakaran,
M.Sastry,
G.B.Stewart-Jones,
J.Stuckey,
P.V.Thomas,
T.Tittley,
C.Williams,
B.Zhang,
H.Zhao,
Z.Zhou,
B.R.Donald,
L.K.Lee,
S.Zolla-Pazner,
U.Baxa,
A.Schön,
E.Freire,
L.Shapiro,
K.K.Lee,
J.Arthos,
J.B.Munro,
S.C.Blanchard,
W.Mothes,
J.M.Binley,
A.B.McDermott,
J.R.Mascola,
P.D.Kwong.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
As the sole viral antigen on the HIV-1-virion surface, trimeric Env is a focus
of vaccine efforts. Here we present the structure of the ligand-free HIV-1-Env
trimer, fix its conformation and determine its receptor interactions. Epitope
analyses revealed trimeric ligand-free Env to be structurally compatible with
broadly neutralizing antibodies but not poorly neutralizing ones. We coupled
these compatibility considerations with binding antigenicity to engineer
conformationally fixed Envs, including a 201C 433C (DS) variant specifically
recognized by broadly neutralizing antibodies. DS-Env retained nanomolar
affinity for the CD4 receptor, with which it formed an asymmetric intermediate:
a closed trimer bound by a single CD4 without the typical antigenic hallmarks of
CD4 induction. Antigenicity-guided structural design can thus be used both to
delineate mechanism and to fix conformation, with DS-Env trimers in
virus-like-particle and soluble formats providing a new generation of vaccine
antigens.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |
|